Insmed price to sales ratio INSM

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026: 17.9×
7-year median: 19.8×
Against its 7-year history: 44th; percentile: 0 is its lowest day, 100 its highest
7-year range: 9.2× to 99.1×
Peer median: 7.5×

Insmed's price to sales ratio is 17.9× as of Oct 23, 2026.

That is below its 7-year median of 19.8×, close to the middle of its last 7 years.

Over that time it ranged from 9.2× in Mar 2023 to 99.1× in Nov 2025.

The median for 10 biotech stocks of a similar size is 7.5×.

Price to sales ratio over time

median 19.8×

The dashed line is the 7-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	17.9×	17.9×	84.5×
2025	84.9×	31.1×	99.1×
2024	36.3×	10.4×	41.2×
2023	15.8×	9.2×	15.8×
2022	11.2×	9.8×	17.5×
2021	18.6×	15.0×	25.6×
2020	20.1×	9.4×	29.2×
2019	21.1×	16.9×	71.3×
2018	n/m a value too high to mean anything
2017	n/m a value too high to mean anything
2016	n/m a value too high to mean anything
2015	n/m a value too high to mean anything
2014	n/m a value too high to mean anything
2013	147×	130×	151×
2012	144×	25.4×	179×

Against its peers

Companies in Biotechnology nearest Insmed's size, closest first, today.

Company	Price to sales ratio
INSMInsmed	17.9×
INCYIncyte	4.0×
UTHRUnited Therapeutics	8.0×
EXELExelixis	6.6×
NBIXNeurocrine Biosciences	4.3×
HALOHalozyme Therapeutics	8.6×
ALNYAlnylam Pharmaceuticals	6.2×
TECHBIO-TECHNE	9.4×
RGENRepligen	12.7×
ONCBeOne Medicines	7.0×
KRYSKrystal Biotech	20.9×
Peer median	7.5×

Where Insmed ranks

#48of 63Biotech stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Insmed

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.